Aytu BioPharma Inc. reported its fiscal 2025 third quarter results, highlighting a strong performance with a 32% increase in total net revenue, reaching $18.5 million compared to $14.0 million in the same quarter of fiscal 2024. The company's ADHD Portfolio, including products such as Adzenys XR-ODT® and Cotempla XR-ODT®, experienced a 25% increase in net revenue, rising to $15.4 million from $12.3 million in the prior year's third quarter. The Pediatric Portfolio, featuring Karbinal® ER, Poly-Vi-Flor®, and Tri-Vi-Flor®, saw a significant 77% growth, with net revenue climbing to $3.1 million from $1.7 million. Net income for the quarter was reported at $4.0 million, or $0.65 basic and $0.21 diluted earnings per share, a notable turnaround from a net loss of $2.9 million, or $0.52 net loss per share, in Q3 fiscal 2024. Adjusted EBITDA also saw a substantial increase, reaching $3.9 million compared to $0.9 million in the previous year's third quarter. Additionally, Aytu BioPharma's cash and cash equivalents stood at $18.2 million as of March 31, 2025. The company remains committed to optimizing its commercial prescription infrastructure and is actively pursuing additional in-licensed or acquired products to enhance its CNS-focused sales capabilities and the Aytu RxConnect patient access platform.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.